New stroke drug reduces brain damage by 60 percent in preclinical study
Cambridge researchers have discovered a new drug that could dramatically improve stroke recovery by reducing brain damage caused when blood flow is restored.
List view / Grid view
Cambridge researchers have discovered a new drug that could dramatically improve stroke recovery by reducing brain damage caused when blood flow is restored.
Scientists have isolated a sugar molecule from deep-sea bacteria that triggers pyroptosis - a form of inflammatory cell death - to halt tumour growth - highlighting the potential of marine microbes in drug development.
Scientists at The Pirbright Institute have developed and successfully tested three experimental vaccines to protect pigs against the deadly Nipah virus - a first step to preventing transmission to humans.
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
Scientists from Fudan University have halted the progression of ALSP, a rare and fatal brain disease, using a pioneering microglia replacement therapy - marking the first effective clinical approach to tackling the disease.
The mouth heals wounds rapidly - and without scarring. A new preclinical study has identified a unique molecular pathway responsible for this ability - which could lead to future skin healing therapies.
Scientists from Nagoya University have developed a fast and safe method to create lung cells from skin-like fibroblasts - without using stem cells. This technique could allow for new regenerative therapies for diseases like chronic obstructive pulmonary disease (COPD).
Researchers at Tel Aviv University have developed a new mouse model that accurately mimics a rare and severe genetic disorder caused by mutations in the GRIN2D gene – allowing for study of the disease’s progression and the testing of potential drug therapies.
QTX153, a novel HDAC6 inhibitor, has shown significant symptom reversal in preclinical models of Rett syndrome. This represents progress toward a therapy for a condition with no approved options.
As ethical pressures and new regulations shake up preclinical research, the industry faces a turning point: can we finally move beyond non-human primates? Dr Mariana Argenziano, Associate Director Manufacturing Technologies at Ncardia, discusses the innovations reshaping drug development and what’s coming next.
MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.
A hormone produced in the gut, FGF19, has been shown to act directly on the brain to boost energy expenditure, burn fat and improve blood sugar control in obese mice - offering a potential route for developing new obesity therapies.
Scientists at the University of Sydney have discovered a malfunctioning brain protein linked to Parkinson’s - which could lead to new therapies for the debilitating condition in the future.
A new study reveals that blocking the enzyme ST6Gal-I reduces toxic plaque buildup in Alzheimer’s disease by suppressing BACE1 expression - highlighting a new target for future treatment strategies.
How do new cancer drugs make it to patients? This episode uncovers the challenges, successes, and AI advancements driving oncology treatments from preclinical screening to clinical trials.